

From: Handley, Gray (NIH/NIAID) [E]
Sent: Mon, 23 Jan 2017 22:01:26 +0000
To: Chen, Ping (NIH/NIAID) [E]
Cc: (b) (6); Meegan, James (NIH/NIAID) [E]; Bernabe, Gayle (NIH/NIAID) [E]; Rosa, William (NIH/NIAID) [E]; Eng, Janette (NIH/NIAID) [E]
Subject: RE: Jan Update

Very helpful report, Ping. Looks like you are pretty busy.

I have copied Janette Eng who can help with your EID registration.

See you soon.

Gray

From: Chen, Ping (NIH/NIAID) [E]
Sent: Friday, January 20, 2017 2:41 AM
To: Meegan, James (NIH/NIAID) [E] (b) (6); Handley, Gray (NIH/NIAID) [E] (b) (6); Bernabe, Gayle (NIH/NIAID) [E] (b) (6); Rosa, William (NIH/NIAID) [E] (b) (6)
Cc: (b) (6)
Subject: Jan Update

Hi All,

Here are the few things I am working on.

1. The intramural TB lab will launch its clinical trial--Predict Trial--in Henan in March. It is an international multi-site clinical trial in China and South Africa to shorten the standard treatment for drug-sensitive TB from 6 months to 4 months by using the imaging technology to predict the prognosis of patients in response to the standard TB therapy. Three sites in Henan are selected. The investigator initiation meeting will be held on Saturday, March 11 at Zhengzhou. In conjunction with this event Henan Provincial Bureau of Health is organizing a conference on TB for the China's Central Region on March 10. Some internationally renowned TB researchers (several from South Africa attending both events) will be invited to attend conference. (b) (5)

(b) (5)

2. (b) (5)

3. I finally received the revised draft meeting outline (without agenda) for the NIAID-CAMS AMR workshop from DMID and shared it with CAMS. The workshop is scheduled for the week of Sept 18

(There is an AMR meeting in Seoul Sept 14-16. Some of the DMID people can come for both meetings). The POC from CAMS for this meeting is Dr. Jiandong Jiang, who is the director of CAMS' Institute of Materia Medica. Gray, we met him during our visit to the institute. He has responded and agreed to the proposed contents of the workshop. I am going to meet him on Feb. 16 to discuss the details. The revised outline is attached for your reference. (b) (5)

4. Two days ago I received the notice that ARLG issued selection decision letters to the hospitals we visited in Dec. 5 hospitals are selected: 2 in Beijing, one in Shanghai and 2 in Hangzhou (for your information Dr. Lanjuan Li's hospital, Shulan is on the selected list). GSK has provided assistance and will continue to provide help on training and trial monitoring. (b) (5)

5. One MOST-sponsored TB treatment clinical trial has started using some CTCTC hospitals (CTCTC is TB clinical trial network DAIDS has provided technical and training supports). One of the CTCTC sites in Wuhan has been chosen to implement our RePort system.

6. DEA will hold a NIAID post award policy and management event in Beijing. Its Beijing host is Dr. Yiming Shao, who should not be a stranger to you (he accompanied Dr. Li to visit NIAID) and our grantee on HIV vaccine. Paula asked me if I can facilitate the issue of invitation letter by Shao. I offered to send invitation letter to her and other help she may need in Beijing.

7. I plan to attend the US-Japan EID meeting in Seoul. However, the link for registration sent by Gayle does not work. I have the hotel reservation already. I will need help to register if the link continuously gives me the error message.

8. A group called Global Virome Project will be visiting Beijing to discuss the scope of the project, which is sponsored by USAID and other organizations. They plan to have US and China be the leaders of the project. The China host is China CDC and our dear friend George Gao is China POC for this project. The purpose of the project is to identify viruses present in the wild life with potential crossing over to humans, causing human infection and disease. Following the identification of the viruses is the development of vaccines to protect human population. China has huge capacity for vaccine development (I think it has 7 national owned vaccine manufacturing facility and over 30 private vaccine making companies). (b) (5) One of the partners in this project is EcoHealth Alliance. Peter Daszak from EcoHealth Alliance is one of the leaders for the GVP project and he has NIAID grant from RDB looking at the coronaviruses in Bat populations in China in collaboration with Wuhan Institute of Virology. He came to visit me once in the Embassy. This grant has direct connection with the purpose of GVP. The meeting is scheduled for Feb. 6-7 in Beijing and it is conflict with our Japan EID meeting.

Thank you and have a nice weekend.

Ping

Ping Chen, PhD
Director of NIAID Office in China
Office of Global Research, NIAID, NIH
Bethesda Office: (b) (6)
BB: (b) (6)
Beijing Office: (b) (6)

Cell: [REDACTED] (b) (6)

U.S. Embassy Beijing
#55 An Jia Lou Road
ChaoYang District, 100600
Beijing, China

[REDACTED] (b) (6)

[REDACTED] (b) (6)